SM Challenge

PROGRAM DESCRIPTION

Join us for an immersive CME COMPETE™ activity, where education meets friendly competition. This interactive, case-based program energizes clinicians as they refine their approach to diagnosing and managing nonadvanced systemic mastocytosis (SM). Learners will navigate scenario-driven challenges that emphasize the importance of high-sensitivity molecular assays, accurate disease classification, and effective use of patient-reported outcomes. Expert faculty will guide teams through current therapeutic options, including approved targeted agents and late-stage investigational therapies shaping the evolving SM landscape. By earning points through data-driven decision-making, participants will strengthen their ability to individualize care and improve outcomes for patients living with nonadvanced SM. 

TARGET AUDIENCE

This activity is designed to educate a primary audience of allergy/immunology, dermatology, and related clinicians attending and interested in AAAAI.

EDUCATIONAL OBJECTIVES

Upon completion of this activity, the participant should be better able to:

1. Explain the pathophysiology of nonadvanced SM, including driver mutations, mast cell hyperactivation, and the scientific rationale for targeted therapy.
2. Apply updated diagnostic criteria (World Health Organization [WHO]/International Consensus Classification [ICC]) and integrate clinical cues, biomarkers, and genetic testing to improve timely and accurate diagnosis.
3. Summarize current and emerging therapies for nonadvanced SM, including trial evidence and FDA-approved targeted treatments.
4. Develop personalized treatment strategies that balance efficacy, safety, patient-reported outcomes, shared decision-making, and patient education, including trigger avoidance, anaphylaxis preparedness, and access to advocacy/resources. 

DISCLOSURES OF CONFLICTS OF INTEREST

Integritas Communications adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content are required to disclose all financial relationships with any ineligible company within the past 24 months to Integritas. All financial relationships reported are identified as relevant and mitigated by Integritas in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by Integritas to assure objectivity and that the activity is free of commercial bias. 

All relevant financial relationships have been mitigated.

The faculty have the following relevant financial relationships with ineligible companies:

Brian Chernak, MD: Consulting Fees: Cogent Biosciences, Geron Corporation, Sobi

Matthew P. Giannetti, MD: Consulting, medical safety board: Cogent Biosciences, Inmagene; Research funding: Blueprint Medicines Corporation

Anne Maitland, MD, PhD: Consulting Fees: Blueprint Medicines Corporation; Fees for Non-CE Services Received Directly from an Ineligible Entity or their Agents (e.g., speakers’ bureaus): Blueprint Medicines Corporation

DISCLOSURE OF UNLABELED USE

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration. Integritas Communications does not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

DISCLAIMER

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

FEE INFORMATION & REFUND/CANCELLATION POLICY

There is no fee for this educational activity.

INTEGRITAS CONTACT INFORMATION

For questions about this activity, please contact us at info@exchangecme.com.